Chan Chin-Hong, Huang Hsiang-Hsiung, Lin Ching-Heng, Kuan Yi-Chun, Loh El-Wui, Lan Tsuo-Hung
Department of Psychiatry, Centro Hospitalar Conde de São Januário, CHCSJ, Macau, China.
Department of Psychiatry, Tungs' Taichung Metro Harbor Hospital, Taichung, Taiwan.
J Clin Psychiatry. 2017 Sep/Oct;78(8):e1006-e1012. doi: 10.4088/JCP.16m11123.
Exposure to selective serotonin reuptake inhibitors (SSRIs) has been shown to increase the risk of stroke. In this study, we investigated age and time effects on the risk of first onset stroke in SSRI-exposed (SSRIEXP) adult subjects.
We analyzed an 8-year cohort from the National Health Insurance Research Database, Taiwan. Patients were defined as SSRIEXP subjects if they received SSRI prescriptions for at least 2 consecutive months during January 1, 2001, to December 31, 2007. Otherwise, they were categorized as SSRI-nonexposed (SSRINONE) subjects. Stroke diagnosis was made according to ICD-9 codes 430-432 (hemorrhagic stroke) and 433-437 (ischemic stroke).
Kaplan-Meier survival analysis showed a greater probability of first onset stroke in SSRIEXP than SSRINONE subjects (P < .001). The higher incidence rates in SSRIEXP subjects persisted to the 3 year time point. Ischemic/hemorrhagic stroke cumulative incidence ratios were also higher during the first 3 years in SSRIEXP subjects. Analysis of adjusted hazard ratios indicated that younger SSRIEXP subjects were more likely to experience stroke, with a slight increase of risk in subjects older than 65 years. Stratified analysis of ischemic stroke and hemorrhagic stroke resulted in a similar hazard ratio trend.
Use of SSRIs independently increases the risk of stroke across age strata. The risk is higher in younger adult subjects, and the stroke is more likely to be ischemic than hemorrhagic. The underlying mechanisms of stroke may be related to cerebral microbleeding or an overcorrection of hemostasis function.
已证明使用选择性5-羟色胺再摄取抑制剂(SSRI)会增加中风风险。在本研究中,我们调查了年龄和时间对暴露于SSRI(SSRIEXP)的成年受试者首次发生中风风险的影响。
我们分析了来自台湾国民健康保险研究数据库的一个8年队列。如果患者在2001年1月1日至2007年12月31日期间连续至少2个月接受SSRI处方,则被定义为SSRIEXP受试者。否则,他们被归类为未暴露于SSRI(SSRINONE)的受试者。中风诊断根据国际疾病分类第九版代码430 - 432(出血性中风)和433 - 437(缺血性中风)进行。
Kaplan - Meier生存分析显示,SSRIEXP受试者首次发生中风的概率高于SSRINONE受试者(P <.001)。SSRIEXP受试者较高的发病率一直持续到3年时间点。在最初3年中,SSRIEXP受试者的缺血性/出血性中风累积发病率也更高。调整后的风险比分析表明,年轻的SSRIEXP受试者更容易发生中风,65岁以上受试者的风险略有增加。对缺血性中风和出血性中风的分层分析得出了类似的风险比趋势。
使用SSRI会独立增加各年龄层的中风风险。年轻成年受试者的风险更高,且中风更可能是缺血性而非出血性。中风的潜在机制可能与脑微出血或止血功能的过度纠正有关。